DocGo investors back reverse split, elect directors
DocGo Inc. held its 2026 annual stockholder meeting, where investors elected two Class II directors, Vina Leite and James M. Travers, to serve until the 2029 meeting.
Rhea-AI Filing Summary
DocGo Inc. held its 2026 annual stockholder meeting, where investors elected two Class II directors, Vina Leite and James M. Travers, to serve until the 2029 meeting. As of the April 20, 2026 record date, 98,778,413 common shares were entitled to vote.
Stockholders approved on a non-binding basis the compensation of the company’s named executive officers and authorized a reverse stock split at a ratio between 1-for-5 and 1-for-10, at the board’s discretion. They also ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026.
Proposed charter amendments to permit broader waivers of corporate opportunities and to add officer liability exculpation did not receive the requisite level of support, so the company’s charter was not amended for those items.
Positive
- None.
Negative
- None.
Insights
Routine annual meeting with reverse split authority granted and two governance changes rejected.
DocGo stockholders approved all routine items, including director elections, executive pay on an advisory basis, and auditor ratification. They also authorized a reverse stock split in a range of 1-for-5 to 1-for-10, leaving the exact ratio to the board.
Two governance-focused charter amendments did not reach the required approval threshold: a corporate opportunity waiver and an officer exculpation provision. This keeps existing fiduciary and liability structures in place. Overall, the meeting outcomes are largely administrative, with future impact depending on whether the board implements a reverse split.
8-K Event Classification
Key Figures
Key Terms
reverse stock split financial
non-binding, advisory basis regulatory
corporate opportunities regulatory
Officer Exculpation Amendment regulatory
broker non-votes financial
independent registered public accounting firm regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What key items did DocGo (DCGO) stockholders approve at the 2026 annual meeting?
What reverse stock split authority did DocGo (DCGO) receive from stockholders?
Which DocGo (DCGO) charter amendments failed to receive sufficient stockholder approval?
Did DocGo (DCGO) stockholders approve executive compensation at the 2026 meeting?
Who was elected to DocGo’s (DCGO) board of directors at the 2026 meeting?
AI-generated analysis. How Rhea-AI works. Not financial advice.